Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Heart Disease & Cardiovascular — Weekly Report — October 26, 2026

Home/Health Insights/Heart Disease & Cardiovascular — October 26 – November 2, 2026
Vol. 7 · No. 46
DoctiPlus Care · Weekly Brief on Heart Disease & Cardiovascular
Updated Sunday · November 15, 2026
Heart Disease & Cardiovascular · October 26 – November 2, 2026

Heart Disease & Cardiovascular
Weekly Report

This week's data 129 new clinical trials registered across 10 countries, with 8,856 trials actively recruiting patients worldwide.
Week of October 26 – November 2, 2026
  • 129 new clinical trials registered across 10 countries.
  • 8,856 trials actively recruiting patients worldwide.
  • Notable trial: A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults Wit... (180000 patients).
  • 3,518 new research papers published.
  • Drug safety: Most reported effect across tracked medications (atorvastatin, lisinopril, metoprolol, amlodipine, warfarin) was Fatigue.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 26 – November 2, 2026
New Trials This Week
129.
registered Oct 26–Nov 2
Recruiting Now
8,856
active trials seeking patients
Countries
10
with active trials this week
Papers Published
3,518
new studies this week
Phase 3 Trials
3
late-stage trials this week
Fig. 01

Trials by country

Count · October 26 – November 2, 2026
United States
81
China
56
Spain
37
Argentina
23
Mexico
18
Italy
18
Turkey (Türkiye)
16
South Korea
16
France
15
Brazil
15
0 21 42 63 81
total
Fig. 02

Trials by phase

Distribution · October 26 – November 2, 2026

New clinical trials registered this week for Heart Disease & Cardiovascular. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

129 trials registered for Heart Disease & Cardiovascular. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Adverse Events During Physical Therapy in Neurocritical ICU Patients Heart Disease & Cardiovascular · Hospital H+ Queretaro (NCT07901140) Other Active Not Recruiting 47 Mexico
02 Neurological Rehabilitation and Neuroplasticity After Ischemic Stroke Heart Disease & Cardiovascular · Medical University of Lodz (NCT07899710) Other Not Yet Recruiting 60 N/A
03 Pulsed Field Ablation of Atrial Fibrillation: CENTAURI Versus FARAPULSE Heart Disease & Cardiovascular · St. Anne's University Hospital Brno, Czech Republic (NCT07902739) Other Completed 325 Czechia
04 Effect of an Electromagnetic Trainer on Gait and Balance Recovery After Stroke Heart Disease & Cardiovascular · Karaganda Medical University (NCT07898657) Other Recruiting 80 Kazakhstan
05 Investigation of Serum Sclerostin Levels in Patients With Erectile Dysfunction Heart Disease & Cardiovascular · Medipol University (NCT07902362) Other Completed 97 Turkey (Türkiye)
06 Effect of Early Tendon Vibrations on Upper Limb Motor Recovery After a Stroke Heart Disease & Cardiovascular · Centre Hospitalier Régional d'Orléans (NCT07905625) Other Not Yet Recruiting 54 France
07 Effects of Mirror Therapy and Motor Imagery on Upper Limb Motor Functions in Middle Cerebral Artery Stroke Heart Disease & Cardiovascular · Lahore University of Biological and Applied Sciences (NCT07902284) Other Recruiting 36 Pakistan
08 Cardiac CT Angiography in Acute Stroke Imaging (SCOPE-CT) Heart Disease & Cardiovascular · Ottawa Hospital Research Institute (NCT07896889) Other Not Yet Recruiting 50 Canada
09 A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions Heart Disease & Cardiovascular · AJU Pharm Co., Ltd. (NCT07901088) Phase 1 Not Yet Recruiting 40 South Korea
10 Comparative Effects of Vestibular Rehabilitation With and Without Cervical JPS Training in Stroke Patients Heart Disease & Cardiovascular · University of Management and Technology Lahore (NCT07905703) Other Active Not Recruiting 50 Pakistan
11 Haemodynamic Effects of Four Sevoflurane Wash-In Strategies After Tracheal Intubation Heart Disease & Cardiovascular · Ataturk University (NCT07894393) Other Completed 102 Turkey (Türkiye)
12 A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk Heart Disease & Cardiovascular · Eli Lilly and Company (NCT07900633) Phase 3 Not Yet Recruiting 3,000 United States
13 Renal Denervation in Patients With Atrial Fibrillation and Hypertension Heart Disease & Cardiovascular · Pavel Antiperovitch (NCT07893821) Other Recruiting 10 Canada
14 The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity Heart Disease & Cardiovascular · Universiti Sains Malaysia (NCT07897409) Phase 2 Not Yet Recruiting 146 Egypt
15 Sevoflurane vs. Propofol for General Anesthesia in Patients With Acute Ischemic Stroke Treated With Endovascular Therapy Heart Disease & Cardiovascular · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (NCT07902791) Phase 3 Recruiting 314 Spain
16 Generative AI and Gamified Simulation-Based Train-the-Trainer Basic Life Support Training for High School Teachers in Vietnam Heart Disease & Cardiovascular · Eastern International University (NCT07898891) Other Not Yet Recruiting 56 Thailand
17 Effects of Adding Vagal Neuromodulation to Manual Therapy in Women With Fibromyalgia Heart Disease & Cardiovascular · Hasan Kalyoncu University (NCT07894588) Other Not Yet Recruiting 44 Turkey (Türkiye)
18 Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients Heart Disease & Cardiovascular · Beijing Anzhen Hospital (NCT07897305) Other Not Yet Recruiting 700 China
19 Risk Factors for Spinal Cord Injury After Minimally Invasive Aortic Repair Heart Disease & Cardiovascular · Assiut University (NCT07896564) Other Not Yet Recruiting 200 Egypt
20 Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis Heart Disease & Cardiovascular · Otsuka Pharmaceutical Development & Commercialization, Inc. (NCT07904806) Phase 2 Not Yet Recruiting 75 N/A
21 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Netherlands) Heart Disease & Cardiovascular · Sanofi (NCT07905508) Other Completed 180,000 Netherlands
22 Music Therapy in Post-Stroke Patients: A Clinical Trial Heart Disease & Cardiovascular · Universidad de Granada (NCT07899034) Other Recruiting 84 Spain
23 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Italy) Heart Disease & Cardiovascular · Sanofi (NCT07906132) Other Completed 93,000 Italy
24 Tenecteplase in Acute Ischemic Stroke Under Different Transfer Models Heart Disease & Cardiovascular · Fujian Medical University Union Hospital (NCT07897955) Other Not Yet Recruiting 2,000 China
25 Cardiac Arrest - Ultrasound Detection of Occult Perfusion Heart Disease & Cardiovascular · University of Massachusetts, Worcester (NCT07897370) Other Recruiting 1,400 United States
26 Auricular Indwelling Needles Added to Diosmin/Hesperidin for Grade I-II Internal Hemorrhoids With Heat-Toxin Syndrome Heart Disease & Cardiovascular · University of Medicine and Pharmacy at Ho Chi Minh City (NCT07899229) Other Not Yet Recruiting 64 N/A
27 Plantar Load Analysis of Neuropathic and Neuroischaemic Diabetes-Related Foot Ulceration Heart Disease & Cardiovascular · The Leeds Teaching Hospitals NHS Trust (NCT07901478) Other Completed 16 United Kingdom
28 Comparison of Negative Pressure Wound Therapy Versus Moist Wound Dressing in Diabetic Foot Ulcer Patients Heart Disease & Cardiovascular · Abbas Institute of Medical Sciences (NCT07898202) Other Not Yet Recruiting 60 Pakistan
29 Comparative Effects of Sensorimotor Training and tACS on Upper Limb Function and Cervical Proprioception in Subacute Stroke Heart Disease & Cardiovascular · University of Management and Technology Lahore (NCT07905716) Other Active Not Recruiting 38 Pakistan
30 Care COMPASS Study Heart Disease & Cardiovascular · Fitbit LLC (NCT07904793) Other Not Yet Recruiting 200 United States
31 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Heart Disease & Cardiovascular · Regeneron Pharmaceuticals (NCT07901725) Phase 3 Not Yet Recruiting 382 N/A
32 A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Spain) Heart Disease & Cardiovascular · Sanofi (NCT07905534) Other Active Not Recruiting 18,000 Spain
33 Safety and Feasibility of NRICM301 Added to Usual Care for Adults With Acute Ischemic Stroke Heart Disease & Cardiovascular · En Chu Kong Hospital (NCT07900503) Other Recruiting 45 Taiwan
34 Effects of Contralateral Gravity Eliminated Gluteus Medius and Ipsilateral Quadratus Lumborum Strengthening on Pelvic Alignment, Balance and Functional Mobility on Subacute Stroke Patients Heart Disease & Cardiovascular · Lahore University of Biological and Applied Sciences (NCT07902310) Other Recruiting 40 Pakistan
35 The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain Heart Disease & Cardiovascular · Germans Trias i Pujol Hospital (NCT07900230) Other Not Yet Recruiting 500 N/A
36 Safety and Efficacy of CG-BM1 in Ischemic Stroke Heart Disease & Cardiovascular · GuangZhou Cellgenes Biotechnology Co., Ltd. (NCT07896941) Phase 2 Recruiting 87 China
37 Decision Support for Chemoprevention Heart Disease & Cardiovascular · Columbia University (NCT07899151) Other Not Yet Recruiting 240 United States
38 IMB-Guided Health Education Intervention for Medication Adherence and Blood Pressure Control in Non-adherent Hypertensive Patients Heart Disease & Cardiovascular · Bahir Dar University (NCT07894068) Other Recruiting 230 Ethiopia
39 CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke Heart Disease & Cardiovascular · Medical University of Graz (NCT07899788) Other Not Yet Recruiting 1,500 Austria
40 Aortic Size and Height Indices in Abdominal Aortic Aneurysms Heart Disease & Cardiovascular · Tecnologico de Monterrey (NCT07893704) Other Not Yet Recruiting 2,000 Mexico
41 Safety of NRICM301 Added to Standard Care in Adults With Acute Ischemic Stroke Heart Disease & Cardiovascular · Tri-Service General Hospital (TSGH) (NCT07902934) Other Not Yet Recruiting 45 N/A
42 Vascular Health and Function in Cystic Fibrosis Heart Disease & Cardiovascular · Liverpool Heart and Chest Hospital NHS Foundation Trust (NCT07904325) Other Not Yet Recruiting 100 United Kingdom
43 Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Heart Disease & Cardiovascular · PETHEMA Foundation (NCT07901868) Phase 2 Not Yet Recruiting 60 Spain
44 Neqpiaput Iinruugut (Our Food Is Medicine): A Tribally Driven Food Sovereignty Intervention to Reduce Heart Disease Risk in Alaska Native Adults Heart Disease & Cardiovascular · University of Alaska Fairbanks (NCT07897838) Other Not Yet Recruiting 150 United States
45 Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation Heart Disease & Cardiovascular · Karolinska University Hospital (NCT07899918) Other Not Yet Recruiting 234 Sweden
46 A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China Heart Disease & Cardiovascular · Novo Nordisk A/S (NCT07900438) Phase 4 Recruiting 300 China
47 Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke Heart Disease & Cardiovascular · Xuanwu Hospital, Beijing (NCT07896629) Other Not Yet Recruiting 60 China
48 Virtual Human Twins as Tools for Personalized Clinical Care in Heart Failure With Preserved Ejection Fraction: a Pilot Study Heart Disease & Cardiovascular · Assistance Publique - Hôpitaux de Paris (NCT07902453) Other Not Yet Recruiting 60 France
49 A Comparison of Pulsed Field Ablation (PFA) vs Cryoablation for Atrial Fibrillation Under Deep Sedation Heart Disease & Cardiovascular · East Sussex Healthcare NHS Trust (NCT07900685) Other Recruiting 60 United Kingdom
50 CANCER SCREENING PROGRAM ON UNCERTAINTY, ANTİCİPATORY ANXIETY, CANCER AWARENESS, AND E-HEALTH LITERACY IN A STROKE PATIENTS Heart Disease & Cardiovascular · Ondokuz Mayıs University (NCT07904247) Other Active Not Recruiting 88 Turkey (Türkiye)
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Heart Disease & Cardiovascular. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
atorvastatin Fatigue 1,084
lisinopril Fatigue 1,493
metoprolol Fatigue 1,783
amlodipine Fatigue 2,132
warfarin Off Label Use 239

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Heart Disease & Cardiovascular. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

3,518 papers

Recently published peer-reviewed studies related to Heart Disease & Cardiovascular, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Comprehensive echocardiographic assessment of the left atrium in daily practice: a practical guide. Anwar AM et al. 10.1007/s40477-026-01251-8
View abstract

The left atrium (LA) is a crucial component of cardiovascular performance. A thorough understanding of LA anatomy, physiology, and pathology is necessary for diagnostic and prognostic purposes in daily clinical practice. LA volume is widely recognized as a novel biomarker for cardiovascular risks in the general population. Furthermore, it has been shown to be a significant prognostic factor in various cardiac conditions, such as atrial fibrillation, ischemic heart disease, valvular heart disease, and heart failure. The assessment of LA function in physiologic and pathologic states has gathered interest with expanding research supporting its utility as a biomarker for outcomes in different cardiovascular abnormalities. Utilizing basic and advanced echocardiographic modalities and integrating multiple parameters helps in both qualitative and quantitative assessment of LA size and function. This is a narrative review provides a comprehensive approach to assessing LA size and function by interpreting existing English-language literature, including landmark studies, reviews and consensus documents from leading echocardiography societies. The literature search focused on key terms, such as LA size, phasic function, strain, and Doppler hemodynamics. By collecting, analyzing, and grouping the echocardiographic parameters, we introduce a simplified approach to guide clinicians through a comprehensive LA assessment ranging from standard 2D dimensions to advanced deformational tracking tailored to specific clinical indications.

Journal of ultrasound 2026 Nov 1 PubMed
02 The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): translation and cross-cultural adaptation into Danish and Norwegian and initial psychometric evaluation of the Norwegian version. Rosenberg T et al. 10.1007/s11136-026-04415-5
View abstract

PURPOSE: The Steroid Symptom Questionnaire - Multiple Myeloma (SSQ-MM) was developed to assess patient-reported side effects of corticosteroid treatment in multiple myeloma (MM) patients. This study aimed to translate and culturally adapt the SSQ-MM into Danish and Norwegian, and to provide an initial evaluation of the psychometric properties of the Norwegian version. METHODS: Translation and cultural adaptation followed ISPOR good practice guidelines, including forward-backward translation and cognitive debriefing interviews with patients and clinicians. Psychometric evaluation was conducted in newly diagnosed Norwegian MM patients receiving weekly dexamethasone. Internal consistency was assessed using Cronbach's alpha. Construct validity was explored through correlations with EORTC QLQ-C30 constructs and known-groups comparisons based on ECOG performance status. Responsiveness was evaluated across three time points. RESULTS: The Danish and Norwegian translations were considered relevant and acceptable by patients and clinicians. The Norwegian version demonstrated acceptable internal consistency for the total score (α = 0.74) and psychological subscale (α = 0.81). Correlation patterns were generally consistent with predefined hypotheses and known-groups validity was supported by differences in symptom scores according to ECOG performance status. Responsiveness analyses demonstrated significant increases in the total score and several steroid-related symptoms during treatment, whereas fewer changes were observed following treatment discontinuation. Overall, symptom levels were lower than those reported in the original Australian validation study. CONCLUSIONS: Findings from the Norwegian cohort provide preliminary evidence supporting the reliability, construct validity, known-groups validity, and responsiveness of the Norwegian SSQ-MM. Further studies in larger, diverse MM populations are needed to further evaluate its measurement properties.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2026 Nov 1 PubMed
03 [Electrocardiographic signs of coronary occlusion not meeting STEMI criteria]. Tomcsányi J et al. 10.1556/650.2026.33726
View abstract

The authors describe the electrocardiographic signs of coronary occlusion that do not fall within the STEMI category. Since immediate coronary angiography is required for these patients as well, the ECG signs being presented have great clinical significance. Orv Hetil. 2026; 167(44): 1759-1763.

Orvosi hetilap 2026 Nov 1 PubMed
04 Chronic disease burden and health-related quality of life among missouri adults. Lima Dos Santos SP et al. 10.1007/s11136-026-04422-6
View abstract

PURPOSE: This cross-sectional study examined associations between chronic disease burden, specific chronic conditions, and Short Form 36 (SF-36) health-related quality of life (HRQoL) scores among Missouri adults 18 years of age or older. METHODS: We analyzed survey-weighted data from the 2024 Center for Medical Epidemiology and Population Health Adult Health Survey (N = 547). The primary chronic condition count included cardiovascular disease, chronic respiratory disease, arthritis, diabetes, depressive disorder, non-skin cancer, and kidney disease and was categorized as zero, one, or two or more conditions. Obesity was examined as a condition-specific exposure and in sensitivity analyses. Survey-weighted linear regression models adjusted for age, sex, race/ethnicity, educational attainment, employment status, and rurality. The Benjamini-Hochberg procedure was used to control the false discovery rate across the 10 HRQoL outcomes. RESULTS: Overall, 30.0% of Missouri adults had two or more of the seven selected chronic conditions. Compared with adults with no chronic conditions, adults with two or more conditions had lower scores for nine of the 10 HRQoL outcomes after false discovery rate correction. The largest adjusted differences were observed for Role-Physical (β = -30.65; 95% CI, -46.56 to -14.74), Physical Functioning (β = -28.70; 95% CI, - 38.60 to -18.81), Bodily Pain (β = -28.28; 95% CI, -38.96 to -17.59), Social Functioning (β = -26.18; 95% CI, -35.43 to -16.92), and General Health (β = -24.18; 95% CI, - 30.75 to - 17.62). Physical Component Summary (PCS) was 12.82 points lower (95% CI, -16.98 to -8.66), and Mental Component Summary (MCS) was 6.10 points lower (95% CI, -9.47 to -2.73). Arthritis and cardiovascular disease had the strongest associations with lower PCS, while depressive disorder had the strongest association with lower MCS. In supplementary continuous-count models, each additional condition was associated with a 4.57-point lower PCS score and a 2.20-point lower MCS score. CONCLUSIONS: Greater chronic disease burden was associated with poorer physical and mental HRQoL among Missouri adults. Adding HRQoL assessment to chronic disease surveillance and clinical follow-up may help identify functional limitations and mental health needs that are not apparent from diagnoses alone.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2026 Nov 1 PubMed
05 Posterior Leaflet Restoration for Secondary Mitral Regurgitation: EXPLORE MR Results. Schäfer U et al. 10.1016/j.jcin.2026.10.013
View abstract

BACKGROUND: Secondary mitral regurgitation (MR) contributes to morbidity and mortality in patients with symptomatic valve disease. Although transcatheter edge-to-edge repair is beneficial, many patients remain suboptimal candidates. Posterior leaflet restoration (PLR) provides a prosthetic coaptation surface via an adaptive coaptation element that inflates during systole and deflates during diastole to facilitate leaflet coaptation. OBJECTIVES: This study aims to evaluate the safety and feasibility of PLR using the MRace implant (Polares Medical, Inc). METHODS: Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant in Georgia and Brazil (EXPLORE MR) enrolled 78 symptomatic patients with severe secondary MR (≥3+), stratified post hoc by left ventricular end-diastolic volume: nonseverely enlarged left ventricle (NSELV) (N = 46) and severely enlarged left ventricle (SELV) (N = 32). The primary endpoint was 30-day mortality; secondary endpoints were MR reduction and functional outcomes. RESULTS: The implant was successfully deployed in 96.2% of patients. All-cause mortality at 30 days was 6.4%. MR ≤2+ was achieved in 93.8% of patients at 30 days and was sustained in 90.6% at 1 year. Patients with NSELV showed better results in MR ≤1+ at every time point (94.4% at 30 days, 89.5% at 1 year) compared with the SELV group (79.3% and 69.2%, respectively). The NSELV subgroup demonstrated better functional recovery, with NYHA functional class I or II rising from 8.7% to 84.2%, vs a more attenuated response in the SELV group (15.6%-76.9%). The 6-minute walk test improved in the paired NSELV cohort (Δ +93.9 m), but not in paired patients with SELV (Δ -7.8 m). Kaplan-Meier 1-year all-cause mortality was 29.5% overall and was better in patients with NSELV (19.4%) than in SELV (41.7%). CONCLUSIONS: PLR with the MRace implant achieves substantial MR reduction and meaningful functional improvement, most pronounced in patients without severely enlarged left ventricles. (XPLORE MRace [BR]: Early Feasibility Experience of Posterior Leaflet Restoration to Reduce Mitral Regurgitation Using the MRace Implant [EXPLORE MRace]; NCT06113354).

JACC. Cardiovascular interventions 2026 Oct 31 PubMed
06 Short-Term Anticoagulation vs Dual Antiplatelet Therapy Following Left Atrial Appendage Closure: 1-Year Results of the ANDES Trial. Rodés-Cabau J et al. 10.1016/j.jacc.2026.10.049 Journal of the American College of Cardiology 2026 Oct 31 PubMed
07 The State of Health in Jordan, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study. Al-Ajlouni YA et al. 10.1002/hsr2.73461
View abstract

BACKGROUND: Jordan's health system has evolved amid rapid urbanization and the strain of hosting one of the world's largest refugee populations per capita. This study comprehensively evaluates national disease burden trends in Jordan from 1990 to 2023 to inform health priorities. METHODS: Using the Global Burden of Disease (GBD) 2023 framework, we analyzed age-standardized rates of disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) across 370 diseases and 88 risk factors. Data were derived from national censuses, health surveys, disease registries, and hospital records, and harmonized using standardized GBD modeling and estimation procedures. Analyses were stratified by age, sex, and cause. RESULTS: Between 1990 and 2023, age-standardized DALYs declined by 33.88% (95% UI: -37.38 to -30.59), with greater reductions in males (-38.83%; -42.22 to -35.60) than females (-27.22%; -31.33 to -23.58). YLLs decreased by 49.38% (-50.93 to -47.68), while YLDs remained comparatively stable (2.49%; -2.37 to 7.47). Using mutually exclusive GBD Level 3 causes, ischemic heart disease and diabetes mellitus were the two leading causes of DALYs in 2023. Diabetes mellitus rose from 7th place in 1990 to 2nd place in 2023, while neonatal disorders declined from 1st to 7th place. Metabolic risks remained important contributors to the overall disease burden. Jordan's age-standardized diabetes DALY rate in 2023 was approximately 1.56 times the global rate. CONCLUSION: Jordan's health profile has shifted toward a greater burden from noncommunicable diseases, while age-standardized health loss and premature mortality have declined substantially. In contrast, nonfatal disability changed comparatively little. These findings provide an evidence base for primary prevention of NCDs and for long-term strategies addressing the country's evolving health challenges.

Health science reports 2026 Nov PubMed
08 Mimicking in vivo Inflammation: A New in vitro Model of Endothelial Inflammation to Advance the Study of IMID-Associated Cardiovascular Diseases. Parra P et al. 10.2147/JIR.S635143
View abstract

BACKGROUND: Patients with immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE), face a markedly increased risk of cardiovascular disease (CVD). This is mainly driven by chronic systemic inflammation, which in turn triggers endothelial activation and dysfunction. OBJECTIVE: We aimed to establish a pathophysiologically relevant in vitro endothelial activation model using sub-nanogram concentrations of cytokines to mimic the low-grade systemic inflammatory milieu observed in active IMIDs. METHODS: Human umbilical vein endothelial cells (HUVECs) were exposed to a combination of three key proinflammatory cytokines at circulating pathophysiological concentrations, representative of active clinical disease -interleukin-1 beta (IL-1β) at 20 pg/mL, tumor necrosis factor (TNF-α) at 50 pg/mL, and interferon-gamma (IFN-γ) at 100 pg/mL- referred to as the MIX. Each individual cytokine was also tested, and a high-dose IL-1β control (10 ng/mL) was included as a standard supra-physiological positive control. Surface marker expression was analyzed by flow cytometry, and cytokine/chemokine release was quantified by multiplex assay. RESULTS: At 24 h, the MIX triggered a particular endothelial activation state. Notably, it significantly upregulated key immunological surface markers, including vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1), compared to the untreated control. Furthermore, the MIX significantly increased the release of key chemokines, such as IL-8, interferon-gamma inducible protein-10 (IP-10), and monocyte chemotactic protein-1 (MCP-1), displaying a distinct cooperative profile compared to individual low-dose cytokines. CONCLUSION: Our study demonstrates that the combination of IL-1β, TNF-α, and IFN-γ at pathophysiologically relevant, sub-nanogram concentrations, can successfully model key features of IMID-associated endothelial activation by driving immune marker upregulation and secretory activity, opening new avenues towards the development of physiologically relevant in vitro system for future research into IMID-associated CVD.

Journal of inflammation research 2026 PubMed
09 Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy. Eckmann C et al. 10.1093/jacamr/dlag226
View abstract

Infections caused by multidrug-resistant Gram-negative (MDR-GN) bacteria, particularly carbapenem-resistant organisms (CROs), constitute a significant burden in critically ill patients (CIPs). A multidisciplinary, collaborative approach is essential for responsible antibiotic use in CIPs, balancing the necessity for effective treatment with mitigation of antimicrobial resistance (AMR). While the efficacy of existing antibiotics against CROs is increasingly limited due to resistance development and suboptimal pharmacokinetic/pharmacodynamic properties, several barriers impede the widespread adoption of new agents, including selective susceptibility testing, limited availability, high costs, and concerns regarding the fostering of resistance. Antimicrobial stewardship (AMS) strategies aim to optimize antibiotic use; however, there is an ongoing debate between restrictive and enabling approaches for new antibiotics in CIPs with CRO infections. While restrictive strategies focus on limiting antibiotic use to mitigate resistance, they may delay necessary treatment and negatively impact professional culture. Enablement strategies promote informed decision-making and accessibility when needed but require substantial workforce and expertise. In this narrative review and expert opinion, we propose an algorithm supporting a coordinated AMS approach in CIPs, emphasizing the importance of early diagnosis and appropriate therapy. We advocate for an enablement strategy for new antibiotics in CIPs with MDR-GN infections, aiming to reduce mortality and toxicity associated with older agents. This strategy should be integrated into local AMS programmes under the guidance of experienced clinicians.

JAC-antimicrobial resistance 2026 Dec PubMed
10 A Practical Update on Percutaneous Coronary Intervention (PCI) for the General Physician, Answering Questions of Patient Type, Timing, and Device Choice. Ong HT et al. 10.2147/IJGM.S602972
View abstract

BACKGROUND: Since its inception in the 1970s, percutaneous coronary intervention (PCI) has undergone significant advances. This review provides an updated perspective on PCI to assist general physicians in navigating various clinical presentations, determining the appropriate patient and optimal timing for intervention, as well as selecting appropriate devices for different populations. METHODS: Clinical trials from a targeted three-stage PubMed search, focusing on PCI indications, procedural timing, and device selection, were analyzed and integrated with consensus guidelines from leading cardiology organizations. RESULTS: For patients presenting with ST-elevation myocardial infarction (STEMI), PCI is recommended within 12 h of the onset of symptoms, ideally achieving a door-to-balloon time of 90-120 min from the first medical contact. Beyond the 12 h mark, the procedure remains indicated for those exhibiting persistent ischemia, clinical symptoms, or complications such as shock, arrhythmia, or heart failure. In cases of non-STEMI (NSTEMI), patients generally benefit from PCI during their initial hospital stay, although an early invasive approach may not provide clinical advantages for frail elderly individuals. Complete revascularization is typically favored over treating only the culprit lesion, except in instances of cardiogenic shock. For those with chronic coronary syndrome (CCS), while PCI enhances quality of life and improves symptom management, most clinical trials report that it does not significantly reduce mortality or major cardiovascular incidents. The initial plain old balloon angioplasty faced complications of restenosis and acute vessel closure. While bare metal stents addressed acute closure, the problem of restenosis persisted and stent thrombosis was noted. Current drug-eluting stents (DESs) are the preferred choice owing to superior clinical outcomes, with lower restenosis and stent thrombosis rates. Although theoretically ideal, bioresorbable scaffolds (BRSs) are still undergoing further research since they have yet to prove superior to DESs in clinical trials. In addition, drug-coated balloons (DCBs) have become a specialized treatment, especially for managing in-stent restenosis. CONCLUSION: The necessity for and timing of PCI are dictated by the patient's specific clinical presentation. Immediate intervention is critical for STEMI patients, within 12 h of onset, or those with complications, while NSTEMI cases should be treated during the hospital admission. For CCS, PCI serves as an elective option to alleviate symptoms without altering long-term survival. The DES remains the primary tool in modern PCI, with BRS still undergoing research trials and DCBs serving specialized roles.

International journal of general medicine 2026 PubMed
11 Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation. Wei W et al. 10.2147/TCRM.S612081
View abstract

Circulating biomarkers, particularly cell-free DNA (cfDNA), are transforming contemporary medicine through their capacity to provide dynamic, minimally invasive assessments of disease dynamics. Their clinical utility has broadened substantially to include oncology, cardiovascular conditions, transplant monitoring, infectious diseases, and persistent inflammatory disorders. Nevertheless, the increasing complexity and volume of biomarker-related data pose substantial challenges, necessitating the integration of artificial intelligence (AI) and machine learning methodologies for improved data interpretation, risk assessment, and clinical decision-making. This review presents a thorough examination of recent progress in the integration of circulating biomarkers with AI within therapeutic contexts and clinical risk management. It outlines the translational trajectory from molecular signatures to precision medicine, addresses present constraints, and explores prospective developments. The objective of this review is to serve as a systematic resource for both clinical practice and research, thereby promoting the evolution of personalized medicine through innovative, biomarker-driven strategies supported by AI.

Therapeutics and clinical risk management 2026 PubMed
12 Extracorporeal Cardiopulmonary Resuscitation With Ventricular Unloading in Fulminant Influenza A (H1N1) Perimyocarditis: A Case Report. Marchetti MF et al. 10.1155/crcc/6129145
View abstract

BACKGROUND: Fulminant perimyocarditis is an uncommon cause of cardiogenic shock and refractory cardiac arrest. We describe Influenza A (H1N1)-associated perimyocarditis managed with a stepwise extracorporeal resuscitation strategy. CASE: A 54-year-old woman presented with chest pain, hypoxemia, and cardiogenic shock. Electrocardiography (ECG) showed diffuse ST-segment elevation. Echocardiography revealed severe biventricular dysfunction and a fibrinous pericardial effusion and coronary angiography excluded obstructive disease. Despite vasoactive support and mechanical circulatory support with microaxial flow pump Impella CP (flow 2.7 L/min.), she deteriorated to Society for Cardiovascular Angiography and Interventions (SCAI) Stage E with pulseless electrical activity (PEA). During automated chest compressions, mechanical circulatory support with femoral Impella CP was rapidly escalated to venoarterial extracorporeal membrane oxygenation (VA-ECMO). Respiratory polymerase chain reaction (PCR) was positive for Influenza A (H1N1) virus. Antiviral therapy, heparin anticoagulation, ventilation, and organ support were instituted. Hemodynamics stabilized, lactate cleared, and neurological examination after decannulation was intact. Progressive myocardial recovery permitted VA-ECMO explant on Day 3 and Impella CP removal 24 h thereafter. She was extubated on Day 6 and discharged from intensive care unit (ICU) on Day 10. Cardiac magnetic resonance (CMR) imaging confirmed myocarditis; echocardiography at follow-up showed preserved biventricular function. CONCLUSION: In fulminant perimyocarditis with refractory arrest, rapid activation of an extracorporeal cardiopulmonary resuscitation (ECPR) pathway with early VA-ECMO-combined with ventricular unloading-can bridge to myocardial recovery and favorable neurological outcome. Regional systems enabling safe transfer under continuous cardiopulmonary resuscitation (CPR) are critical.

Case reports in critical care 2026 PubMed
13 Beyond Blood-Brain Barrier Crossing in Reperfusion-Era Ischemic Stroke: Interface-Matched Active-Entity Delivery and Translational Product Design. Bu F et al. 10.2147/IJN.S650851
View abstract

Reperfusion therapy has transformed acute ischemic stroke care, yet large-vessel recanalization does not ensure capillary reperfusion, preservation of the blood-brain barrier and neurovascular unit (BBB/NVU), or durable neurological recovery. Nanomedicine is still commonly judged by BBB crossing or ischemic-hemisphere accumulation, although vascular access, tissue viability, transport phenotype, thromboinflammation, and standard treatment change rapidly during the lifetime of a formulation. This narrative review proposes a conceptual framework that matches the reperfusion state and pathological interface to the compartment in which the therapeutically active entity must act. The framework is intended to organize preclinical evidence and generate testable translational hypotheses; it has not yet been clinically validated. Persistent occlusion may favor intravascular targets, whereas recanalization with no-reflow creates a distinct microvascular delivery problem. Early reperfusion injury may prioritize BBB/NVU stabilization, while later biological contexts may require selective immune, regenerative, or organelle-directed interventions. These contexts may coexist spatially, vary across vascular territories, and shift during treatment; they should therefore not be interpreted as a mandatory chronological sequence. We distinguish BBB crossing, controlled barrier modulation, and BBB/NVU repair as separate therapeutic tasks, and introduce transport attrition as a practical explanation for why sequential targeting, transcytosis, cellular uptake, endosomal escape, and organelle localization can yield little final active-entity exposure despite strong tissue imaging. Recent predominantly preclinical examples illustrate how thrombus-targeted rtPA systems, neutrophil-intercepting particles, NET-degrading polymersomes, lesion-targeted nanoplatforms, and mitochondrial nanomedicines may fit different delivery topologies. Translational credibility requires topology-resolved exposure, target engagement in viable tissue, hemocompatibility under antithrombotic treatment, state-appropriate models, function-linked manufacturing controls, and compatibility with thrombolysis and thrombectomy.

International journal of nanomedicine 2026 PubMed
14 Improvement in mitral regurgitation after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: a retrospective cohort study. Damlin A et al. 10.1186/s12872-026-06952-w
View abstract

BACKGROUND: The primary mechanism of mitral regurgitation (MR) in hypertrophic obstructive cardiomyopathy is systolic anterior motion (SAM) of the mitral leaflets due to septal hypertrophy narrowing the left ventricular outflow tract (LVOT), influencing leaflet movement and closure. Among patients undergoing alcohol septal ablation (ASA), the impact on- and underlying mechanism of MR remains less studied. The aim was to determine the prevalence of MR and changes in MR severity after ASA and analyze echocardiographic (ECHO) parameters associated with MR changes. METHODS: All patients who underwent ASA at Karolinska University Hospital in Sweden, 2009-2021 (follow-up until 2025), were included in this retrospective cohort study. ECHO parameters were collected before ASA, at 1-year follow-up and at the latest follow-up registered. To evaluate differences in continuous values, Kruskal-Wallis test was used, and for categorical values, Fischer's exact test was used. RESULTS: 154 patients were included (mean follow-up 4.0 ± 3.9 years). 14% (n = 21) had at least moderate MR at baseline, of which 90% (n = 19) improved to mild MR or less. The patients with improved (n = 19, 12%) or unchanged (n = 128, 83%) grade of MR showed greater reduction of LVOT peak pressure gradients (improved MR: 137.5 to 4.8 mmHg, unchanged MR: 57.0 to 25.0 mmHg) between baseline and last follow-up, compared with patients with increased MR grade (n = 7, 4.5%, 57.0 to 51.0 mmHg, p = 0.003). CONCLUSIONS: Among patients with at least moderate MR before ASA, MR severity generally improved at follow-up, potentially due to septal reduction and LVOT enlargement, which may have reduced SAM. CLINICAL TRIAL NUMBER: Not applicable.

BMC cardiovascular disorders 2026 Oct 31 PubMed
15 Renin-angiotensin system inhibitors and arterial stiffness in chronic kidney disease: results from the chronic renal insufficiency cohort. Shulman R et al. 10.1038/s41371-026-01241-7
View abstract

Chronic kidney disease (CKD) is associated with accelerated arterial stiffness, which contributes to its high burden cardiovascular disease. There is conflicting evidence on whether renin-angiotensin system inhibitors (RASIs) prevent arterial stiffness. We investigated the association between RASIs versus non-RASI antihypertensive medications and yearly changes in carotid-femoral pulse wave velocity (cfPWV) - a measure of arterial stiffness -using a linear mixed-effects model among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. As a secondary analysis, we restricted the cohort to participants on one antihypertensive medication at baseline. Lastly, we used a linear mixed-effects model to evaluate the relationship between RASI use and systolic blood pressure over time. Of the 1 201 participants who met inclusion criteria, 982 were on RASI and 219 were on a non-RASI medication. Individuals on RASI had a non-significant increase in cfPWV (adjusted cfPWV 0.19 m/s per year, 95% CI 0.14 to 0.25) compared to non-RASI users (adjusted cfPWV 0.15 m/s per year, 95% CI 0.00 to 0.30; p = 0.61). In the monotherapy cohort (N = 283), there was no difference in adjusted yearly change in cfPWV between RASI (0.11 m/s per year, 95% CI 0.02 to 0.21) and non-RASI users (0.03 m/s per year, 95% CI -0.14 to 0.20; p = 0.41). In both cohorts, there was no significant difference in systolic blood pressure over time between RASI and non-RASI users. Future research to mitigate the accelerated large artery stiffness in patients with CKD should focus on targetable mechanisms beyond the renin-angiotensin system.

Journal of human hypertension 2026 Oct 31 PubMed
16 CT-based anatomical and clinical characteristics associated with gastroparesis following cryoballoon ablation for atrial fibrillation. Shimosato H et al. 10.1007/s00380-026-02780-2
View abstract

Periesophageal vagal nerve injury-induced gastroparesis is a rare but significant complication of cryoballoon ablation (CBA) for atrial fibrillation (AF). Data on the utility of pre-procedural computed tomography (CT) imaging for identifying patients at risk remain limited. We retrospectively analyzed 265 consecutive patients with persistent or long-standing persistent AF who underwent pulmonary vein isolation (PVI) and left atrial roof ablation (LARA) using a cryoballoon system. Symptomatic gastroparesis occurred in 5 patients (1.9%). Patients with gastroparesis had a significantly lower body mass index (BMI; 20.0 ± 3.3 vs. 23.8 ± 3.5 kg/m², P = 0.008). During LARA, the number of cryoballoon applications with esophageal temperature < 25 °C was higher (1.0 ± 0.6 vs. 0.3 ± 0.5, P = 0.004) and the nadir temperature was lower (21.3 ± 7.7 vs. 28.2 ± 6.3 °C, P = 0.01). CT analysis showed a longer left atrium (LA)-esophagus contact length and shorter distances between the esophagus and adjacent structures (spine and aorta) in patients with gastroparesis. All cases recovered with conservative treatment. Lower BMI, wider atrial-esophageal contact on CT, and lower esophageal temperature during LARA were associated with gastroparesis following CBA. Pre-procedural CT imaging may help identify patients at higher risk and inform procedural strategies to minimize periesophageal nerve injury.

Heart and vessels 2026 Oct 31 PubMed
17 Updates in cardiovascular CT imaging in 2025: A year in review. Nagpal P et al. 10.1016/j.jcct.2026.09.012
View abstract

The year 2025 brought long-term outcome data supporting coronary CT angiography (CCTA)-guided management of stable chest pain, a proposed reframing of coronary artery disease around atherosclerosis rather than ischemia, and the first large-scale real-world evaluation of a national artificial intelligence (AI)-enabled CT-derived fractional flow reserve (FFR-CT) program. This review summarizes selected advances in cardiovascular computed tomography (CCT) published in print or online during 2025. The studies span coronary artery disease outcomes and prevention, quantitative plaque analysis, photon-counting detector CT, coronary artery calcium scoring, pericoronary inflammation imaging, AI and machine learning, structural and congenital heart disease, and consensus and training documents. For each study we summarize the design, principal findings, limitations, and likely clinical implications, and we close with the barriers, including technical standardization, vendor-specific thresholds, equitable access, and the need for randomized outcome trials, that must be addressed before many of these advances can be implemented broadly.

Journal of cardiovascular computed tomography 2026 Oct 31 PubMed
18 Social and Environmental Exposures and the Developing Gut of Newborns With Congenital Heart Disease. John AS et al. 10.4037/ajcc2026557
View abstract

BACKGROUND: Dysbiotic gut microbiomes are linked to morbidity, mortality, and poor outcomes, so it is critical to understand their influencing factors. OBJECTIVES: To investigate the impact of nosocomial and socioecological factors on the gut microbiome in newborns with congenital heart disease (CHD). METHODS: This was a secondary analysis of a prospective cohort of newborns with CHD matched to healthy newborns by age, sex, and race and ethnicity. Data on feeding type and routes and disease-related factors were collected from electronic medical records. Stool samples were collected at 3 perioperative time points. Gut microbiome diversity and abundance were analyzed using QIIME 2. RESULTS: Newborns with CHD (n = 41) showed higher alpha diversity (P = .007) and dissimilar beta diversity (P = .001) versus controls (n = 40). Beta diversity was dissimilar between those receiving human milk versus formula (P = .05), between those receiving fortified versus nonfortified human milk (P = .04), and between those receiving naso-orogastric tube feeds versus other routes (P = .02). Newborns with CHD fed only human milk had higher relative abundance of Haemophilus (P = .04), those with longer duration of aortic cross-clamping had lower relative abundance of Streptococcus (P = .10), and those of higher socioeconomic deprivation had higher relative abundance of Enterococcus (P = .03). CONCLUSIONS: Feeding tubes, formula exposure, aortic cross-clamp, and socioeconomic status were associated with altered gut microbiome diversity. Further study is needed to determine the causal relationships leading to gut microbial dysbiosis in newborns in the cardiac intensive care unit.

American journal of critical care : an official publication, American Association of Critical-Care Nurses 2026 Nov 1 PubMed
19 Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase to Treat High-Risk Pulmonary Embolism. Haber A et al. 10.4037/ajcc2026126
View abstract

BACKGROUND: The optimal dosing of alteplase in patients with high-risk pulmonary embolism is widely debated. OBJECTIVE: To evaluate outcomes in patients with high-risk pulmonary embolism who received alteplase at a low dose or a standard dose. METHODS: This was a retrospective cohort analysis of 65 patients who received alteplase for high-risk pulmonary embolism at a large academic medical center between June 1, 2011, and August 31, 2022. Patients were placed in 2 cohorts according to initial dose: low-dose alteplase (50 mg) and standard-dose alteplase (100 mg). The primary outcome was sustained hemodynamic stability within 24 hours of the start of alteplase infusion. Secondary outcomes included in-hospital mortality, duration of mechanical ventilation, hospital and intensive care unit length of stay, and major bleeding. RESULTS: The primary outcome of sustained hemodynamic stability within 24 hours did not differ significantly between the 2 cohorts (achieved in 32% of patients in the low-dose group and 38% in the standard-dose group; P = .65). In-hospital mortality did not differ significantly between groups (48% in the low-dose group vs 45% in the standard-dose group; P = .81). Patients in the low-dose group had fewer days of mechanical ventilation than patients in the standard-dose group (1.5 vs 6 days; P = .03) and a smaller percentage had major bleeding (12% vs 25%; P = .34). CONCLUSIONS: In patients with high-risk pulmonary embolism, sustained hemodynamic stability within 24 hours did not differ significantly between low-dose and standard-dose alteplase treatment strategies. Low-dose alteplase may be an appropriate alternative dosing strategy for patients with high-risk pulmonary embolism.

American journal of critical care : an official publication, American Association of Critical-Care Nurses 2026 Nov 1 PubMed
20 'Sex differences in surgical left-sided infective endocarditis' - Author's reply. Tomasino M et al. 10.1016/j.cmi.2026.10.032 Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2026 Oct 31 PubMed
21 Immunomodulatory therapies in bacterial community-acquired pneumonia: Current evidence and future directions. Flower L et al. 10.1016/j.cmi.2026.10.031
View abstract

BACKGROUND: Community-acquired pneumonia remains a leading cause of morbidity and mortality worldwide, accounting for more than two million deaths annually. While most patients successfully clear pulmonary infection through an effective host immune response, a subset progress to severe disease characterised by dysregulated and excessive inflammation. This maladaptive immune response drives subsequent organ dysfunction and mortality, prompting increasing interest in immunomodulatory therapies as adjunctive treatments. OBJECTIVES: This article aims to describe the key immunomodulatory strategies investigated for the management of bacterial community-acquired pneumonia, summarise the evidence for their efficacy and limitations, and highlight potential future therapeutic approaches. SOURCES: We conducted a comprehensive literature search of Medline, Embase, Web of Science, Scopus and Global Health, using search terms related to pneumonia and immunomodulatory intervention from database inception to December 8, 2025. CONTENT: While a broad range of immunomodulatory strategies has been investigated in bacterial community-acquired pneumonia, few have been shown to be reliably beneficial. Corticosteroids are the most extensively studied agents and have been associated with clinically relevant outcomes in selected patient populations, supporting guideline recommendations for their use in severe community-acquired pneumonia. Targeted inhibition of inflammatory cytokines and downstream signalling pathways has been explored to a lesser degree, with limited evidence supporting its use in bacterial community-acquired pneumonia. Other approaches, including passive immunotherapy and immune stimulation, have been investigated, but current evidence supporting their routine use remains inconclusive. IMPLICATIONS: Immunomodulation represents an important adjunctive therapeutic strategy in bacterial community-acquired pneumonia. Although progress has been made, particularly with corticosteroids, evidence remains incomplete. Further high-quality research is required to better define patient selection, optimal timing, and the clinical impact of immunomodulatory therapies.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2026 Oct 31 PubMed
22 The surgery was a success but … who was the patient? Lurie F et al. 10.1016/j.ejvs.2026.10.038 European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2026 Oct 31 PubMed
23 Carotid and femoral plaque burden in patients with early coronary artery disease events: Prevalence, extent and relationship to risk phenotypes. López-Melgar B et al. 10.1016/j.ijcard.2026.135023
View abstract

BACKGROUND: Early coronary artery disease events (eCAD) are increasing, occasionally occurring in individuals with minimal atherosclerosis, suggesting heterogeneous underlying mechanisms. We report, for the first time, carotid and femoral plaque burden in eCAD patients, relate it to underlying phenotypes, and compare it with the PESA reference cohort to explore preventive implications. METHODS: eCAD patients (<60 years) were consecutively and prospectively enrolled at a tertiary hospital. Conventional and non-conventional cardiovascular risk factors (CVRF) and blood biomarkers were assessed, and global atherosclerosis plaque burden (GPB) was quantified as total carotid and femoral plaque volume by 3-dimensional vascular ultrasound (3DVUS). RESULTS: Among 231 eCAD patients (53 ± 5 years old; 14% women; 23% with a prior event; 52% presented with STEMI) conventional CVRF were frequent but prevalence of non-conventional CVRF was high (28% elevated lipoprotein a, 25% family history of eCAD, 25% hyperuricemia, and 14% hyperhomocysteinemia). Underlying GPB was high (268.7 mm3 [IQR75.2-509.9]), being higher in the femoral than the carotid territory (200.6 mm3 [IQR51.7-420.7] vs 35.2 mm3 [IQR7.9-96.2], p < 0.001), and increased with age. Compared with age-matched asymptomatic individuals (PESA study), eCAD patients had markedly higher GPB (284.1 mm3 [IQR110-546.8] vs 50.8 mm3 [18.7-121.5]). However, GPB in eCAD patients varied widely. Severe GBP (percentile≥75th) identified a subgroup with predominantly conventional CVRF and prior CAD, with marginal presence of non-conventional factors, compared with those with no-or-mild GPB (percentile≤25th). CONCLUSION: Carotid and femoral PB by 3DVUS identifies distinct pathophysiological phenotypes in eCAD, underscoring the value of atherosclerosis assessment for individualized management and prevention.

International journal of cardiology 2026 Oct 31 PubMed
24 Title: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI). Kwok TS et al. 10.1016/j.jbspin.2026.106156
View abstract

OBJECTIVE: To determine the prevalence and factors associated with coexisting gout in rheumatoid arthritis (RA) and evaluate whether concomitant gout is associated with worse RA disease activity. METHODS: We conducted a retrospective study of RA patients enrolled in the Ontario Best Practices Research Initiative, a multicentre real-world cohort across Ontario, Canada. Coexisting gout was defined by patient- or physician-reported diagnosis or xanthine oxidase inhibitor use. Multivariable logistic regression identified factors associated with coexisting gout and the impact of gout on oral glucocorticoid (GC) use. The association between baseline gout and longitudinal RA disease activity (Clinical Disease Activity Index, CDAI ≤10) was examined using mixed-effects logistic regression at 24-months, adjusting for prespecified confounders. RESULTS: Among 3,703 RA patients, 113 (3.1%) had coexisting gout with mean (SD) age of 66.1 (8.7) years and 52.2% were female. Coexisting gout was associated with older age (OR 1.05 per year), obesity (OR 1.67), cardiovascular disease or hypertension (OR 1.95) and diuretic use (OR 1.68), while female sex was inversely associated (OR 0.31). CDAI scores were similar between patients with and without gout at baseline (18.3±12.5 vs 20.2±13.5) and at 12-months (10.9±9.8 vs 11.0±10.4). After adjustment, baseline coexisting gout was neither significantly associated with oral GC use at 12-months (OR 1.73, 95% CI: 0.96-3.13) or the attainment of CDAI low disease activity/remission by 24-months (OR 1.19, 95% CI: 0.72-1.97). CONCLUSION: In this large real-world RA cohort, coexisting gout was uncommon and associated with traditional gout risk factors but did not statistically influence oral GC use or RA treatment target attainment.

Joint bone spine 2026 Oct 31 PubMed
25 Associations of Skeletal Muscle Mass and Density with Left Ventricular Hypertrophy in Dialysis Patients. Wang XX et al. 10.1053/j.jrn.2026.10.009
View abstract

BACKGROUND: Left ventricular hypertrophy (LVH) is common and prognostically important in dialysis patients, and may be linked to abnormal body composition. We investigated the associations of skeletal muscle radiodensity (SMD) and skeletal muscle index (SMI) with LVH risk in this population. METHODS: We enrolled 2,119 dialysis patients from four tertiary hospitals (2020-2023). Muscle parameters were quantified via L1-level CT scans. LVH was defined as a left ventricular mass index (LVMI) >95 g/m in women and >115 g/m in men, based on echocardiography. Ordinal logistic regression and restricted cubic splines (RCS) assessed associations and dose-response relationships. RESULTS: The mean (SD) age was 54.8 (13.9) years, 60.7% were male, and 67.5% had LVH. After adjustment, compared with Q4, the ORs (95% CIs) for LVH in Q1, Q2, and Q3 were 1.55 (1.17-2.05; P=0.002; E-value 2.47 [upper CI: 1.62]), 1.45 (1.14-1.86; P=0.003; E-value 2.26 [upper CI: 1.54]), and 1.20 (0.95-1.51; P=0.123), respectively (P for trend=0.001). Each 1-SD decrease in SMD was associated with 1.23-fold higher odds of LVH (95% CI: 1.11-1.37; P<0.001). For SMI, compared with the highest quartile, the lowest quartile was associated with a 43% lower risk of LVH (OR=0.57; 95% CI: 0.43-0.75; P<0.001), and a 1-SD decrease in SMI was associated with an OR of 0.76 (95% CI: 0.68-0.85; P<0.001) for LVH. RCS analyses showed linear relationships of SMD and SMI with LVH (P for nonlinear>0.05). CONCLUSIONS: SMD was inversely associated with LVH, whereas SMI showed a positive association in dialysis patients. These findings highlight the need to consider both muscle quality and muscle quantity when evaluating LVH risk in this population.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2026 Oct 31 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Heart Disease & Cardiovascular
  • Week: October 26 – November 2, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 15, 2026 at 9:48 PM
© 2026 DoctiPlus Care Vol. 7 · No. 46 · November 15, 2026 — 30 —